Five Prime Therapeutics, Inc.
(NASDAQ : FPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.84%326.540.0%$4164.11m
NVAXNovavax, Inc. -3.05%134.5679.4%$783.60m
BNTXBioNTech SE -2.80%278.340.0%$777.03m
AMGNAmgen, Inc. 0.12%209.241.4%$532.78m
REGNRegeneron Pharmaceuticals, Inc. 0.53%572.362.7%$454.63m
SNSSSunesis Pharmaceuticals, Inc. -0.33%6.090.7%$425.71m
CCXIChemoCentryx, Inc. -1.26%34.572.9%$397.56m
GILDGilead Sciences, Inc. 0.37%67.241.0%$393.07m
ILMNIllumina, Inc. -0.59%409.153.3%$356.80m
XLRNAcceleron Pharma, Inc. 0.12%173.955.3%$346.86m
VRTXVertex Pharmaceuticals, Inc. -1.91%183.521.9%$275.34m
BIIBBiogen, Inc. -2.00%264.801.7%$255.53m
OCGNOcugen, Inc. -1.66%8.320.0%$187.94m
XENEXenon Pharmaceuticals, Inc. 0.75%30.860.4%$166.06m
CRSPCRISPR Therapeutics AG -1.55%95.560.6%$159.15m

Company Profile

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.